The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
01. October 2026
Berlin, 1 October 2026
In its final arbitration ruling, the arbitration board (Schiedsstelle) considers a 15% discount on the reimbursement amount to be appropriate, as negotiated in an analogous procedure …
09. September 2026
Berlin, 9 September 2026
The Federal Joint Committee (GBA) is giving itself a new visual identity. The logo is being revised as well: the previous “G-BA” becomes the word mark …
07. September 2026
For the active substance onasemnogene abeparvovec (Itvisma®) for the treatment of 5q spinal muscular atrophy (SMA) in patients aged 2 years and older with a biallelic mutation in the survival …
Key data from all AMNOG decisions, summarized in a compact and structured format.
Analyze your own research questions by filtering across more than 120 parameters.
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.
